companion still thrive guid rais
minim flow-through outlook
revenu vs our/street core growth
organ basi ex-abaxi fx headwind beat led
companion anim strength innov dermatolog portfolio simparica although
livestock result also better-than-fear due favor mix price increas
opex control margin came well-ahead gm opm adj ep
ahead street larg oper top-lin margin
gain first look detail
stellar perform continu tougher go
mani way result reminisc result broad strength companion
anim portfolio led dermatolog portfolio contribut sale growth
above-averag price gain growth abaxi portfolio sale much
focu call upcom product launch tripl combo
receiv favor opinion eu still expect hit market
chang prior monoclon antibodi pain cat approv well
solid execut margin gain seen ytd notabl rais guid
organ sale growth gm vs prior still impli signific
deceler half year management attribut larg tougher comp
includ lap abax acquisit think updat outlook appropri
see substanti uncertainti potenti risk either direct
season downstream impact african swine fever abaxi sale ramp ie
management expect double-digit sale growth mix shift oper leverag
updat estim rais po stay neutral
tweak estim half year
chang model result beat rais po higher
ep po still base price-to-earnings reiter neutral rate
valuat remain all-time-high believ expect alreadi reflect
much upsid ie tripl combo launch initi sale ramp
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth howev
see valuat full given expect
alreadi high see limit room
po base ep estim back dcf
assum wacc termin growth rate roughli in-lin
current multipl albeit slightli higher recent valuat trend
believ justifi given upsid new product launch increment capit
deploy margin expans opportun defens natur
upsid risk continu ramp new product larger-than-expect contribut
futur launch acceler growth abaxi acquisit
downsid risk price object competit select market new product
launch competitor weaker demand anim health product regulatori issu
failur get approv key product pipelin macroeconom
condit currenc risk headwind relat regul antibiot use
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
